Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...

Pipeline & Trials: Apellis Pharmaceuticals stands out with its C3 inhibitor, pegcetacoplan (Syfovre), offering novel treatment options for PNH and GA, with positive Phase III trial results. Treatment ...

William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of ...

WALTHAM, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its second quarter 2024 financial results and business highlights. “We have continued to ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for geographic atrophy (GA), Syfovre, may have hit a performance “nadir” in 2024’s ...

Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of ...

Please provide your email address to receive an email when new articles are posted on . The FDA approval of Izervay has provided a second welcomed treatment option for geographic atrophy, with good ...

Received U.S. FDA approval for EMPAVELI ® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN Announced capped royalty purchase agreement with Sobi under which ...